Gene expression of the secreted glycoprotein Dkk-3 is upregulated during cellular senescence in prostate basal epithelial cells and altered in age-related disorders of the human prostate. In order to quantify the influence of such age-and diseaserelated changes of Dkk-3 levels in body fluids, we established a highly specific and sensitive indirect IEMA. Results revealed a significant increase of Dkk-3 blood plasma levels in the elderly indicating a non negligible physiological role and its use as a marker for senescence not only in vitro but also in vivo.
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Introduction
The secreted glycoprotein Dkk-3 is the most divergent member of the human Dickkopf family (Krupnik et al., 1999; Niehrs, 2006) and in contrast to other family members does not modulate Wnt signaling (Mao et al., 2001; Wu et al., 2000) . Our previous results indicated a possible link between Dkk-3 expression and age associated processes in the human prostate. Serial analysis of gene expression (SAGE) of human prostate basal epithelial cells revealed specific induction of DKK3 gene during cellular senescence (Untergasser et al., 2002) in vitro. In a recent immunohistochemical study (Zenzmaier et al., 2008) we demonstrated, that Dkk-3 is downregulated in vivo in prostate epithelium of patients suffering from age-related prostate diseases (benign prostatic hyperplasia, BPH and prostate carcinoma, PCa).
This downregulation is counterbalanced by increased protein expression in the endothelial cells of the blood vessels supplying the diseased tissue.
To investigate if the identified cellular senescence-related changes in expression became manifest in body fluids, particularly in human blood plasma, we developed a sensitive indirect immunoenzymometric assay (IEMA).
Materials and Methods
Generation and characterization of monoclonal antibodies
A series of mouse monoclonal antibodies (mAbs) against Dkk-3 was raised according to methods published for mAbs against FSH (Berger et al., 1988) . To produce recombinant protein for the immunization, the DKK3 ORF was cloned in-frame upstream of the E epitope tag (GAPVPYPDPLEPR) into the expression vector pcDNA3.1 (Invitrogen). COS7 cells were transiently transfected with the construct 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -4 -and the protein was purified from the conditioned media via affinity chromatography using a column packed with Anti-E Tag Sepharose (GE Healthcare).
Radioimmunoassays
Antibodies were characterized according to affinity and specificity with native (untagged) Dkk-3 that was purified via HPLC (anion exchange followed by size exclusion chromatography) from conditioned media of stably transfected LNCaP cells (Zenzmaier et al., 2008) and the commercially available homologous proteins Dkk-1, Dkk-4 and Soggy-1 (R&D systems). The proteins were radiolabelled with 125 I using chloramine T. Antibodies were incubated over night at 4°C with radiolabelled protein (approximately 25 000 cpm in 100 µL 0.3% BSA in PBS). Separation of bound from free tracer was achieved by 2 h incubation at room temperature on a shaker with 100 µL immunoabsorbent (donkey anti-mouse IgG or donkey anti-goat IgG; Guildhay, respectively, coupled to bromide-activated Sepharose CL-4B beads; GE Healthcare).
After 3 times washing with 0.5% Tween-80 in PBS bound radioactivity was determined in 1470 WIZARD automatic gamma counter (Wallac).
Sensitive IEMA protocol
An indirect IEMA was established using mAb INN(sbruck)-Dkk3-1 at a concentration of 4 µg/mL in coating buffer (200 mM NaHCO 3 ; pH 9.5; incubation for 1 h at 37°C) to 
Probands
Blood plasma samples were obtained from 63 healthy donors. The local ethical committee approved the bleeding protocol and all participants provided informed consent. A medical history was obtained and individuals with malignancies, acute diseases or advanced stages of severe chronic diseases were excluded from the study. Persons who were under immunosuppressive therapy were also excluded as well as persons under medication for type II diabetes.
Results
A series of mouse monoclonal antibodies (mAbs) against Dkk-3 was raised. Six of these antibodies and an affinity purified goat polyclonal antibody (R & D Systems)
were then characterized according to affinity and specificity with recombinant Dkk-3 and the homologous proteins Dkk-1, Dkk-4 and Soggy-1 (R&D systems). None of the tested antibodies had significant affinities towards the homologous proteins. The   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Given the specific induction of Dkk-3 during in vitro cellular senescence of human prostate basal epithelial cells (Untergasser et al., 2002) , protein expression during aging was analyzed in vivo. Blood plasma samples from 63 healthy individuals from two age cohorts were investigated (for proband characteristics see Table 1 ). A mean concentration of 1.42  0.56 nM Dkk-3 (n = 63) was determined, corresponding to 51.3  20.3 ng/mL of the non-glycosylated protein. There were no significant sexspecific differences in the obtained protein levels (female: n=33, meanSD: 1.42  0.62 nM; male: n=30, meanSD: 1.41  0.49). When the data were analyzed according to probands´ ages, a significant increase (37.6%; p < 0.01; Figure 2A ) of the mean blood Dkk-3 levels was observed. The age cohorts were further subdivided 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -7 -and the age-related increase of the mean plasma protein concentration was confirmed for both sexes (female: 32.5%, p = 0.03; male: 44.2%, p < 0.01; Figure   2B ). The mean values obtained from the single groups are listed in Table 1, a scatter plot of all individual values is depicted in Figure 2C .
Discussion
To our knowledge this is the first quantitative determination of secreted Dkk-3 protein Despite its homology to the Wnt antagonist Dkk-1, Dkk-3 does not modulate Wnt signaling (Mao et al., 2001; Wu et al., 2000) . Due to its downreguation in a number of cancer cells (Hsieh et al., 2004; Kurose et al., 2004; Tsuji et al., 2000; Tsuji et al., 2001 ) Dkk-3 was considered to function as a tumor suppressor but when studying the effect of Dkk-3 on cell growth of either primary prostate cells or BPH and PCa cell lines it appeared that proliferation rates were neither impaired by overexpression nor addition of recombinant protein (Zenzmaier et al., 2008) . Thus the biological role of the protein remains unclear.
The origin of the Dkk-3 in blood plasma is not resolved either. One source could be 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 -8 -endothelial cells, were Dkk-3 is reported to be expressed (Goodwin et al., 2006; Kupatt et al., 2005) . Moreover, we detected high expression of Dkk-3 in vascular endothelial cells in BPH and PCa tissue sections (Zenzmaier et al., 2008) .
Upregulation of the protein in tumor endothelium has also been demonstrated in colorectal carcinoma, glioma, high-grade NHL and melanoma (St Croix et al., 2000; Untergasser et al., 2008) . Therefore Dkk-3 can be considered a pro-angiogenic protein in neovascularisation. High expression of the protein was also seen in a subset of adult human pancreatic beta cells (Hermann et al., 2007) . These cells could also contribute to the Dkk-3 levels determined in human blood plasma.
The established assay may help to elucidate the mechanism by which the protein acts, as it gives us the opportunity to quantify differences in Dkk-3 secretion in in vivo
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